Back to top

Array BioPharma (ARRY) is in Overbought Territory: What's Next?

Read MoreHide Full Article

Array BioPharma Inc. (ARRY - Free Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because ARRY is now in overbought territory with an RSI value of 72.03.

What is RSI?       

RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.

Other Factors

Yet ARRY’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions in Array BioPharma’s stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of ARRY’s prospects for the near term.

Over the past two months, investors have witnessed 2 earnings estimates revision lower compared to one higher for the current year. The consensus estimate for ARRY has also been on a downward trend over the same time period too, as the estimate has fallen from -$0.79/share two months ago to just -$0.82/share today.

If this wasn’t enough, Array BioPharma also has a Zacks Rank #4 (Sell)which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth.

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Array BioPharma Inc. (ARRY) - free report >>

More from Zacks Tale of the Tape

You May Like